SCHEMBL20722816

SCHEMBL20722816

COC(=O)[C@H](N)Cc1c(F)c(F)c(N2CCN(C(=O)OCc3ccccc3)CC2)c(F)c1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
DPP4 P27487 1/20 0.46
CYP2C19 P33261 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
KDM4E B2RXH2 1/20 0.43
HTT P42858 1/20 0.43
POLB P06746 1/20 0.42
GFER P55789 1/20 0.42
HDAC1 Q13547 1/20 0.41
TMEM97 Q5BJF2 4/20 0.41
SIGMAR1 Q99720 4/20 0.41
HTR1A P08908 1/20 0.41
ADRA2A P08913 1/20 0.41
ADRA2B P18089 1/20 0.41
ADRA2C P18825 1/20 0.41
DRD1 P21728 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21685804 1.00 SMN1; SMN2 (0.47) SMN1; SMN2NPC1RAB9ADPP4CYP2C19
SCHEMBL20722564 0.86 DPP4 (0.49) SMN1; SMN2NPC1RAB9ADPP4CYP2C19
SCHEMBL21685820 0.86 DPP4 (0.49) SMN1; SMN2NPC1RAB9ADPP4CYP2C19
SCHEMBL28567927 0.84 SMN1; SMN2 (0.42) SMN1; SMN2NPC1RAB9ADPP4CYP2C19
SCHEMBL20722397 0.82 MEN1 (0.52) SMN1; SMN2NPC1RAB9ADPP4CYP2C19
SCHEMBL20722641 0.81 MEN1 (0.51) SMN1; SMN2NPC1RAB9ADPP4CYP2C19
SCHEMBL20722449 0.76 MEN1 (0.51) SMN1; SMN2NPC1RAB9ADPP4CYP2C19
SCHEMBL30968415 0.76 PARP1 (0.42) SMN1; SMN2NPC1RAB9ADPP4CYP2C19
SCHEMBL13756987 0.75 NPSR1 (0.52) SMN1; SMN2NPC1RAB9ADPP4CYP2C19
SCHEMBL31639673 0.74 SMN1; SMN2 (0.51) SMN1; SMN2NPC1RAB9ADPP4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12162888-B2 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2024-12-10 US disclosed
CN-112867712-B Carboxamide as ubiquitin-specific protease inhibitor 瓦洛早期发现股份有限公司 2024-07-16 CN disclosed
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2022-12-13 US disclosed
US-20210323975-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS VALO EARLY DISCOVERY, INC. 2021-10-21 US disclosed
EP-3833661-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS Valo Early Discovery, Inc. (US) 2021-06-16 EP disclosed
EP-3665169-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS Forma Therapeutics, Inc. (US) 2020-06-17 EP disclosed
WO-2020033707-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS FORMA THERAPEUTICS, INC. (US) 2020-02-13 WO disclosed
WO-2019032863-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS FORMA THERAPEUTICS, INC. (US) 2019-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 SMN1; SMN2 2918/4885NPC1 3743/4885RAB9A 3585/4885
US-20210323975-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS USP28, USP25, USP24 SMN1; SMN2 2918/4885NPC1 3743/4885RAB9A 3585/4885
US-12162888-B2 Carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 SMN1; SMN2 2918/4885NPC1 3743/4885RAB9A 3585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.